";s:4:"text";s:4262:" Less than a month after offering a glimpse at early clinical data for its lead cancer immunotherapy at virtual ESMO, Sensei Biotherapeutics has reeled in $28.5 million to wade deeper into Phase II. CRISPR. For decades, there hasn’t been a solution. There are two main types of CRISPR-based editing. A growth hormone treatment that’s seen a turbulent path may finally be reaching the light at the end of the tunnel. We believe that the alarm being sounded by the scientific community isn’t really about ethics. It’s been two months since Chinese scientist He Jiankui shocked the world with the announcement that his lab had created the first genetically edited babies. It shouldn’t be up to a group of scientists, and certainly not up to the GMO-fearing general public, to decide broadly whether or not genome modification is ethical. The research community widely agreed that He and his colleagues crossed an ethical line with the first inheritable genetic modification of human beings. Nina Frahm is a research associate at the Innovation, Society and Public Policy Research Group at the Munich Center for Technology in Society at the Technical University Munich and a visiting research fellow with the Program on Science, Technology, and Society at the Harvard Kennedy School of Government. CRISPR gene editing is a genetic engineering technique in molecular biology by which the genomes of living organisms may be modified. Yet in defending He, Church argued that a moratorium “is not a permanent ban forever.” Instead, any proposed moratorium can be seen as a checklist for what scientists think should happen before technological advance proceeds. Rather than being seen as an anomaly, He’s actions should be a reminder of the tensions routinely produced by our long-standing culture of scientific self-governance. They don’t consider whether it should take place at all, or how to deal with subsequent uses and future consequences of such technological capacities once they are the purview of the market and not of scientific ethics. Says CEO May: “We’re trying to connect the data across the healthcare ecosystem.”, Bioscience & Technology Business CenterThe University of KansasLawrence, Kansas. Reactions to He’s announcement reveal instead anxiety on the part of the scientific community about “knee-jerk” regulations that would make it more difficult to do gene-editing research, not to mention damage to the public’s trust in gene editing. Prospects include correcting congenital monogenic disorders, targeting disease-causing molecular lesions, 1 and even altering multiple genetic loci at the same time. They also called for the creation of international bodies that could counsel scientists and governments and track reports of scientists, such as He Jiankui, carrying out potentially dubious projects. Now, by using CRISPR to edit the genome in pig organs, researchers seem well on their way to solving that problem. One of two different candidates Moderna was helping push forward in a hotly competitive space, the vaccine had entered Phase I last year.